A low eutectic solvent with antibacterial effect, liposome and preparation method and application thereof

Abstract

The present invention relates to a low eutectic solvent with antibacterial effect, a liposome and a preparation method and application thereof, and belongs to the technical field of antibacterial products. The low eutectic solvent of the present invention comprises paeonol and totarol, wherein the molar ratio of paeonol to totarol is (1-9): (1-9); the low eutectic solvent is combined with an antioxidant active substance, an emulsifier and an auxiliary component, and simply mixed to obtain a liposome with antibacterial effect, and further prepared into a product with antibacterial effect. The present invention uses antibacterial active substances from specific natural sources, combined with active substances with anti-inflammatory and soothing effects, to form a low eutectic solvent, which has stronger stability and higher safety. Paeonol and totarol, two antibacterial raw materials, are compounded and combined to form a low eutectic solvent, so that the two antibacterial ingredients have synergistic effects and the antibacterial effect is stronger. The liposome of the present invention encapsulates the antibacterial raw materials that are not easily water-soluble, improves the water solubility of the raw materials, and at the same time, the preparation process is simple and the application is more convenient.

Description

Technical Field

[0001] The present invention relates to the technical field of antibacterial products, and in particular to a low eutectic solvent with antibacterial effect, a liposome, and a preparation method and application thereof. Background Art

[0002] Adding appropriate antibacterial agents to food, medicine, and cosmetics can inhibit and kill microorganisms, and play an important role in ensuring stable product quality and safety. Choosing a suitable preservative system should take into account both the antibacterial effect and environmental safety, as well as interference with other ingredients, which is the focus of research and development. However, the safety issues of the use of traditional antibacterial agents deserve attention. Traditional antibacterial agents are highly irritating. For example, in cosmetics, some antibacterial agents may irritate the skin. In severe cases, they may cause clogged pores or chronic poisoning of the mucous membranes, leading to skin allergic dermatitis, or photosensitivity reactions, and even carcinogenic risks.

[0003] Natural antibacterial agents are generally isolated and extracted from plants, animals or microorganisms and used in the field of food, medicine and cosmetic antibacterial agents. Natural antibacterial agents include plant-derived antibacterial agents (such as plant essential oil antibacterial agents) or microbial-derived preservatives. Natural antibacterial agents are green, pollution-free, mild and highly safe, so they have attracted widespread attention. However, there is a problem that natural antibacterial agents are not effective enough. The analysis of the active ingredients of plant-derived antibacterial agents is not complete, the batches are not uniform, and the stability is poor. Plant essential oil antibacterial agents cannot be mutually dissolved in water that is prone to bacterial growth; the residual enzymes of microorganisms in microbial-derived preservatives after the microorganisms are killed cause product deterioration and other problems that limit the application of natural preservatives.

[0004] Therefore, antibacterial agents with low skin irritation, high safety, high stability, clear ingredients, easy solubility in water and significant antibacterial efficacy are worthy of study. Summary of the invention

[0005] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a low eutectic solvent with antibacterial effect, liposomes and their preparation method and application.

[0006] To achieve the above object, the technical solution adopted by the present invention is:

[0007] In a first aspect, the present invention provides a deep eutectic solvent (DES) with antibacterial effect, comprising paeonol and totarol, wherein the molar ratio of paeonol to totarol is (1-9): (1-9).

[0008] The present invention uses specific antibacterial substances as hydrogen bond donors and hydrogen bond acceptors to prepare a low eutectic solvent. Studies have found that among the antibacterial substances, paeonol and totarol can be combined to obtain DES. Moreover, paeonol and totarol can only form DES within a specific molar ratio range.

[0009] As a preferred embodiment of the low eutectic solvent of the present invention, the molar ratio of paeonol to totarol is (1-4): (1-2). Within this range, a uniform liquid DES can be prepared at a relatively lower temperature and in a relatively shorter time.

[0010] In the second aspect, the present invention provides a method for preparing the deep eutectic solvent (DES) with antibacterial effect: paeonol and totarol are mixed according to the molar ratio, reacted at 50-100°C for 20-180 minutes, cooled to room temperature, and the resulting liquid is the deep eutectic solvent. In the conditions of the preparation method, paeonol and totarol cannot be melted when the reaction temperature is lower than 50°C, and the drug activity may be affected when the reaction temperature is higher than 100°C. If the reaction time is too short, the two components are not completely combined, and if the time is too long, the activity may be affected.

[0011] In a third aspect, the present invention provides use of the deep eutectic solvent (DES) having antibacterial effect in preparing liposomes.

[0012] In a fourth aspect, the present invention provides a liposome, comprising, by mass percentage: 10-30% of the deep eutectic solvent (DES), 1-35% of antioxidant active ingredients, 15-50% of emulsifiers and 5-50% of auxiliary ingredients; the auxiliary ingredients are at least one of glycerol, 1,3-propylene glycol, 1,2-propylene glycol, 1,2-butylene glycol, 1,2-hexanediol, 1,2-pentanediol or ethylhexylglycerol.

[0013] As a preferred embodiment of the liposome of the present invention, the liposome includes, by mass percentage: 25-30% of the deep eutectic solvent (DES), 10-20% of antioxidant active substances, 35-40% of emulsifiers, and 10-20% of auxiliary ingredients. Within this range, the particle size of the liposome is smaller and the stability is better.

[0014] As a preferred embodiment of the liposome of the present invention, the auxiliary component is 1,3-propylene glycol or 1,3-butylene glycol.

[0015] As a preferred embodiment of the liposome of the present invention, the antioxidant active substance is at least one of vitamin E polyethylene glycol succinate (TPGS), vitamin E (VE), tocopherol acetate, vitamin A (VA), superoxide dismutase (SOD), glutathione (GSH) or ubiquinone (coenzyme Q).

[0016] As a preferred embodiment of the liposome of the present invention, the antioxidant active substance is vitamin E polyethylene glycol succinate (TPGS) or vitamin E (VE).

[0017] As a preferred embodiment of the liposome of the present invention, the emulsifier is at least one of polysorbate-20 (Tween-20), polysorbate-40 (Tween-40), polysorbate-60 (Tween-60), polysorbate-80 (Tween-80), oleth-5, laureth-4, PEG-40 hydrogenated castor oil or polyglycerol-10 oleate.

[0018] As a preferred embodiment of the liposome of the present invention, the emulsifier is polysorbate 20 (Tween-20) or polysorbate 80 (Tween-80).

[0019] In a fifth aspect, the present invention provides a method for preparing the liposome, comprising mixing the low eutectic solvent, antioxidant active substance, emulsifier, and auxiliary components in proportion to form a uniform liquid to obtain the liposome.

[0020] As a preferred embodiment of the method for preparing liposomes of the present invention, the mixing is carried out at 20-50°C.

[0021] As a preferred embodiment of the method for preparing liposomes of the present invention, the mixing is carried out at 40°C.

[0022] In a sixth aspect, the present invention provides the use of the liposome in preparing an antibacterial product.

[0023] In a seventh aspect, the present invention provides an antibacterial product, comprising the liposome.

[0024] Compared with the prior art, the present invention has the following beneficial effects:

[0025] The invention discloses a low eutectic solvent with antibacterial effect, comprising paeonol and tortoside, wherein the molar ratio of paeonol to tortoside is (1-9): (1-9); the low eutectic solvent is combined with an antioxidant active substance, an emulsifier and an auxiliary component, and simply mixed to obtain a micro-liposome with antibacterial effect, and further prepared into a product with antibacterial effect. The invention uses antibacterial active substances from specific natural sources, combined with active substances with anti-inflammatory and soothing effects, to form a low eutectic solvent, which has stronger stability and higher safety. The two antibacterial raw materials of paeonol and tortoside are compounded and combined to form a low eutectic solvent, so that the two antibacterial ingredients have synergistic effects and a stronger antibacterial effect. The micro-liposome of the invention encapsulates the antibacterial raw materials that are not easily water-soluble, thereby improving the water solubility of the raw materials. At the same time, the preparation process of the low eutectic solvent and the micro-liposome of the invention is simple, and the application is more convenient. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1This is the appearance of the paeonol-totarol deep eutectic solvent (paeonol-totarol DES) prepared by using paeonol and totarol in a molar ratio of 1:1 in Example 1 of the present invention; wherein A is paeonol, B is totarol, and C is paeonol-totarol DES.

[0027] Figure 2 The infrared spectrum of the paeonol-totarol deep eutectic solvent (paeonol-totarol DES) of Example 2 in Test Example 1 of the present invention;

[0028] Figure 3 This is the H NMR spectrum of the paeonol-totarol deep eutectic solvent (paeonol-totarol DES) of Example 2 in Test Example 1 of the present invention; wherein A is totarol, B is paeonol, and C is paeonol-totarol DES;

[0029] Figure 4 The DSC spectrum and TG spectrum of the paeonol-totarol deep eutectic solvent (paeonol-totarol DES) of Example 2 in Test Example 1 of the present invention; wherein A is the DSC spectrum of paeonol, B is the DSC spectrum of totarol, C is the DSC spectrum of paeonol-totarol DES, D is the TG spectrum of paeonol, E is the TG spectrum of totarol, and F is the TG spectrum of paeonol-totarol;

[0030] Figure 5 The appearance of the liposome 1 and its aqueous solution of the present invention; wherein A is the liposome 1, and B is the aqueous solution of the liposome 1;

[0031] Figure 6 is the particle size distribution result of the liposome 1 of the present invention;

[0032] Figure 7 This is the potential test result of the liposome 1 of the present invention. DETAILED DESCRIPTION

[0033] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0034] Unless otherwise specified, other materials, reagents, etc. used in the examples can be obtained from commercial sources.

[0035] Example 1

[0036] 1. Screening of deep eutectic solvents (DES) for antibacterial substance combinations

[0037] The present invention selects a combination of multiple substances with antibacterial effects to prepare a low eutectic solvent, and the substances with antibacterial effects include: paeonol, glycyrrhizic acid, palmitic acid, theophylline, phloretin, and totarol. The antibacterial substances are mixed in a molar ratio of 1:1, uniformly, and then placed at 80°C for stirring and reaction for 60 minutes to study whether different combinations of antibacterial substances can obtain DES.

[0038] The results of whether different antibacterial substance combinations form DES are shown in Table 1 below.

[0039] Table 1

[0040]

[0041] The test found that only the combination of paeonol and totarol can produce DES that is a uniform liquid at room temperature, which means that not any combination of substances with antibacterial effects can produce DES.

[0042] 2. Effect of the molar ratio of paeonol to tocopherol on the preparation of deep eutectic solvent

[0043] A deep eutectic solvent (DES) includes paeonol and totarol. Paeonol and totarol are uniformly mixed in different molar ratios (1-15:1-15), and then stirred at 80°C for 60 minutes to study the effect of molar ratio on the preparation of the deep eutectic solvent.

[0044] The effects of different molar ratios of paeonol and tocopherol on the preparation of low eutectic solvents are shown in Table 2.

[0045] Table 2

[0046]

[0047] The results in Table 2 show that DES can only be formed when the molar ratio of paeonol to totarol is within a specific range. DES can be formed when the molar ratio of paeonol to totarol is within the range of (1-9): (1-9), but DES cannot be formed when the molar ratio exceeds this range.

[0048] Further research revealed that when the molar ratio of paeonol to totarol is in the range of (1~4):(1~2), uniform liquid DES can be prepared at a relatively lower temperature and in a relatively shorter time.

[0049] The appearance of the paeonol-totarol deep eutectic solvent (paeonol-totarol DES) prepared by mixing paeonol and totarol in a molar ratio of 1:1 is as follows: Figure 1 As shown, Figure 1 A in is paeonol, Figure 1 B in the formula is totarol. Figure 1 The C in it is paeonol-totarol DES, which is a brown liquid.

[0050] Example 2

[0051] Paeonol and totarol are uniformly mixed in a molar ratio of 1:1, and then stirred and reacted at 70°C for 30 minutes. The mixture is liquid at room temperature to obtain a paeonol-totarol low eutectic solvent (paeonol-totarol DES).

[0052] Example 3

[0053] Paeonol and totarol are uniformly mixed in a molar ratio of 1:1, and then stirred and reacted at 50°C for 180 minutes. The mixture is liquid at room temperature to obtain a paeonol-totarol low eutectic solvent (paeonol-totarol DES).

[0054] Example 4

[0055] Paeonol and totarol are uniformly mixed in a molar ratio of 1:1, and then stirred and reacted at 100°C for 20 minutes. The mixture is liquid at room temperature to obtain a paeonol-totarol low eutectic solvent (paeonol-totarol DES).

[0056] Test Example 1

[0057] (1) Infrared spectrum test

[0058] The infrared spectra of the paeonol-totarol deep eutectic solvent (paeonol-totarol DES) prepared in Examples 1 to 4 and the infrared spectra of paeonol and totarol monomers were measured using a Fourier transform infrared spectrometer (IRSpirit, Shimadzu Corporation, Tokyo, Japan).

[0059] The measurement results show that the infrared spectrum peak position of the paeonol-totarol DES prepared in Examples 1 to 4 is shifted to a certain extent compared with the monomers of paeonol and totarol, proving that the deep eutectic solvent is a new eutectic substance rather than a physical mixture, indicating that the present invention successfully prepares the deep eutectic solvent (DES).

[0060] The infrared spectrum of the paeonol-totarol deep eutectic solvent (paeonol-totarol DES) of Example 2 is as follows: Figure 2 shown.

[0061] (2) Nuclear magnetic resonance hydrogen spectrum test

[0062] 5 mg of the paeonol-totarol DES and the corresponding monomer of paeonol-totarol DES prepared in Examples 1 to 4 were respectively dissolved in 0.6 mL of deuterated chloroform reagent and subjected to nuclear magnetic resonance hydrogen spectrum detection. The nuclear magnetic resonance spectrometer was used: Swiss Bruker, AVANCE NEO 400; frequency 400 MHz; injection volume: 5 mg.

[0063] The measurement results show that the paeonol-totarol DES prepared in Examples 1 to 4 has a certain shift in the hydrogen peak position in the nuclear magnetic hydrogen spectrum compared with the monomers of paeonol and totarol, proving that the deep eutectic solvent is a new eutectic substance rather than a physical mixture, indicating that the present invention successfully prepared a deep eutectic solvent (DES).

[0064] The nuclear magnetic hydrogen spectrum of the paeonol-totarol deep eutectic solvent (paeonol-totarol DES) of Example 2 is as follows: Figure 3 As shown, Figure 3 The A in is totarol, Figure 3 B in the formula is paeonol. Figure 3 The C in it is paeonol-totarol DES.

[0065] (3) Differential scanning calorimetry (DSC) test, thermogravimetric analysis (TG)

[0066] The melting point was determined by differential scanning calorimeter and the thermogravimetric analysis was performed by thermogravimetric analyzer.

[0067] The paeonol-totarol DES and the corresponding substance monomers of paeonol-totarol DES prepared in Examples 1 to 4 were respectively subjected to nitrogen protection at a temperature of -80°C to 100°C and a heating rate of 10°C / min to obtain DSC spectra; under nitrogen protection at a temperature of room temperature to 800°C and a heating rate of 10°C / min to obtain TG spectra.

[0068] The test results show that the melting point of the paeonol-totarol DES prepared in Examples 1 to 4 is lower than that of the monomer paeonol and totarol, and the thermal decomposition temperature of the paeonol-totarol DES is between that of the monomer paeonol and totarol, proving that the deep eutectic solvent is a new eutectic substance rather than a physical mixture. This indicates that the present invention successfully prepares a deep eutectic solvent (DES).

[0069] The DSC spectrum and TG spectrum of the paeonol-totarol deep eutectic solvent (paeonol-totarol DES) of Example 2 are as follows: Figure 4 As shown, Figure 4 A in the figure is the DSC spectrum of paeonol. Figure 4 B in the figure is the DSC spectrum of totarol. Figure 4 C in the figure is the DSC spectrum of paeonol-totarol DES. Figure 4 D in is the TG spectrum of paeonol, Figure 4 E in is the TG spectrum of totarol, Figure 4 F in FIG. 1 is the TG spectrum of paeonol-totarol.

[0070] Example 5

[0071] A liposome comprises, by mass percentage, 10-30% of the deep eutectic solvent (DES), 1-35% of an antioxidant active substance, 15-50% of an emulsifier and 5-50% of an auxiliary component.

[0072] The antioxidant active substance is at least one of vitamin E polyethylene glycol succinate (TPGS), vitamin E (VE), tocopherol acetate, vitamin A (VA), superoxide dismutase (SOD), glutathione (GSH) or ubiquinone (coenzyme Q);

[0073] The emulsifier is at least one of polysorbate-20 (Tween-20), polysorbate-40 (Tween-40), polysorbate-60 (Tween-60), polysorbate-80 (Tween-80), oleth-5, laureth-4, PEG-40 hydrogenated castor oil or polyglyceryl-10 oleate;

[0074] The auxiliary component is at least one of glycerol, 1,3-propylene glycol, 1,2-propylene glycol, 1,2-butylene glycol, 1,2-hexanediol, 1,2-pentanediol or ethylhexylglycerol.

[0075] Liposomes 1 to 20 were prepared using the low eutectic solvent, antioxidant active ingredient, emulsifier, and auxiliary ingredient combination prepared in Example 1. According to the preparation conditions of DES in Example 1, the molar ratio of paeonol to totarol was 1:1, recorded as paeonol-totarol 1:1, the molar ratio of 1:2 was recorded as paeonol-totarol 1:2, the molar ratio of 2:1 was recorded as paeonol-totarol 2:1, and so on.

[0076] The combinations and contents of liposomes 1 to 20 are shown in Table 3 below.

[0077] Table 3

[0078]

[0079] Preparation method of liposomes 1 to 15:

[0080] Under the condition of 40° C. water bath, the low eutectic solvent, antioxidant active substance, emulsifier and auxiliary components are mixed evenly according to proportion to form a uniform liquid, thereby obtaining the liposome.

[0081] Preparation method of liposomes 16-20:

[0082] Under the condition of 20-50° C. in a water bath, the low eutectic solvent, the antioxidant active substance, the emulsifier and the auxiliary components are mixed evenly according to proportion to form a uniform liquid, thereby obtaining the liposome.

[0083] The appearance of the liposome 1 and its aqueous solution is as follows: Figure 5 As shown, Figure 5 A in the figure is liposome 1, Figure 5 B in the figure is the aqueous solution of liposome 1. The results show that the liposome is a brown liquid, and its aqueous solution is a milky white uniform liquid.

[0084] Comparative Example 1

[0085] The liposome of Comparative Example 1 is the same as liposome 1, except that 30% of paeonol-totarol DES is replaced by 30% of paeonol monomer.

[0086] Comparative Example 2

[0087] The liposome of Comparative Example 2 is the same as that of liposome 1, except that 30% of paeonol-totarol DES is replaced by 30% of totarol monomer.

[0088] Test Example 2

[0089] The microliposome of the present invention can be self-emulsified when added into water to form nanoparticles.

[0090] The liposomes 1 to 20 and the liposomes of Comparative Examples 1 and 2 were diluted 200 times with deionized water, and the particle size and potential were measured using a Litesizer DIA 500 particle size analyzer.

[0091] The particle sizes and potentials of liposomes 1-20 and liposomes of Comparative Examples 1 and 2 are shown in Table 4 below.

[0092] Table 4

[0093]

[0094] The results in Table 4 show that the particle size of liposomes 1-20 is 50-190 nm, while the particle size of the comparative liposomes is 250-300 nm, which is significantly higher than that of liposomes 1-20, indicating that only the liposomes prepared by DES composed of paeonol and totarol can have a smaller particle size and higher stability. When the composition and mass percentage of the liposomes are: 25-30% of the deep eutectic solvent (DES), 10-20% of the antioxidant active substance, 35-40% of the emulsifier and 10-20% of the auxiliary component, the particle size of the liposomes is smaller and the stability is better.

[0095] The particle size distribution results of liposome 1 are as follows Figure 6 As shown, the potential test results of liposome 1 are as follows Figure 7 shown.

[0096] Test Example 3

[0097] The antibacterial effect of liposomes was tested by using liposomes 1 to 20 and liposomes of comparative examples 1 and 2 to act on Escherichia coli, Staphylococcus aureus, Candida albicans, and Pseudomonas aeruginosa. The antibacterial experiment was conducted by a third-party testing agency.

[0098] Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa were activated and cultured with tryptic soytone agar medium and tryptic soytone liquid medium at a culture temperature of 35°C; Candida albicans was activated and cultured with Sabouraud dextrose agar medium and Sabouraud dextrose liquid medium at a culture temperature of 25°C.

[0099] Take the frozen strains and inoculate them into the liquid culture medium, shake and shake, seal and place them in a shaker, and culture at a constant temperature for 10-12 hours. Dilute the obtained bacterial suspension 100 times, and then inoculate the diluted bacterial suspension onto the solid culture medium, culture at a constant temperature for 12-14 hours, pick a single colony and inoculate it into the liquid culture medium to obtain an activated bacterial suspension for standby use. Dilute the activated bacterial suspension appropriately with the corresponding liquid culture medium, add it to a 96-well plate (100 μL / well), dilute the liposomes 1-20 and the liposomes of comparative examples 1 and 2 with liquid culture medium (with the microcapsule as 100% concentration), add them to the 96-well plate with the bacterial suspension (100 μL / well), and mix them thoroughly. Culture in a 37°C constant temperature incubator for 16-24 hours, observe the growth of bacteria, record the results, and obtain the minimum inhibitory concentration; the lowest concentration without bacteria growth is taken as the minimum inhibitory concentration.

[0100] The minimum inhibitory concentration of lipocapsule 1-20 against Escherichia coli is 0.07-0.09%, the minimum inhibitory concentration against Staphylococcus aureus is 0.06-0.10%, the minimum inhibitory concentration against Candida albicans is 0.40-0.60%, and the minimum inhibitory concentration against Pseudomonas aeruginosa is 0.30-0.55%, and the minimum inhibitory concentrations are all lower than the minimum inhibitory concentrations of the corresponding bacteria in Comparative Examples 1 and 2, indicating that the antibacterial effect of the lipocapsule 1-20 of the present invention is significantly higher than that of the lipocapsule of Comparative Examples 1 and 2, indicating that the lipocapsule 1-20 prepared by the present invention has better antibacterial effect.

[0101] The antibacterial concentration results corresponding to the liposomes 1 to 3 and the liposomes of Comparative Examples 1 and 2 are shown in Table 5 below.

[0102] Table 5

[0103]

[0104] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A low eutectic solvent with antibacterial effect, characterized in that: The invention is prepared from paeonol and totarol, wherein the molar ratio of paeonol to totarol is (1-9): (1-9); The preparation method of the low eutectic solvent is as follows: paeonol and totarol are mixed according to the molar ratio, reacted at 50-100° C. for 20-180 min, cooled to room temperature, and the obtained liquid is the low eutectic solvent.

2. The deep eutectic solvent according to claim 1, characterized in that The molar ratio of paeonol to totarol is (1-4): (1-2).

3. The method for preparing the deep eutectic solvent according to claim 1 or 2, characterized in that: Paeonol and totarol are mixed according to the molar ratio described in claim 1 or 2, reacted at 50-100° C. for 20-180 min, and cooled to room temperature. The obtained liquid is the low eutectic solvent.

4. Use of the deep eutectic solvent according to claim 1 or 2 in preparing liposomes.

5. A liposome, characterized in that: Calculated by mass percentage, the composition comprises: 10-30% of the low eutectic solvent according to claim 1 or 2, 1-35% of antioxidant active ingredients, 15-50% of emulsifiers and 5-50% of auxiliary ingredients; the auxiliary ingredients are at least one of glycerol, 1,3-propylene glycol, 1,2-propylene glycol, 1,2-butylene glycol, 1,2-hexanediol, 1,2-pentanediol or ethylhexylglycerol.

6. The liposome according to claim 5, characterized in that The liposome comprises, by mass percentage, 25-30% of the low eutectic solvent according to claim 1 or 2, 10-20% of antioxidant active substance, 35-40% of emulsifier and 10-20% of auxiliary ingredients.

7. The liposome according to claim 5, characterized in that The antioxidant active substance is at least one of vitamin E polyethylene glycol succinate, vitamin E, tocopherol acetate, vitamin A, superoxide dismutase, glutathione or ubiquinone; And / or, the emulsifier is at least one of polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-80, oleth-5, laureth-4, PEG-40 hydrogenated castor oil or polyglyceryl-10 oleate.

8. The method for preparing the liposome according to any one of claims 5 to 7, characterized in that: The low eutectic solvent, antioxidant active substance, emulsifier and auxiliary components are mixed in proportion to form a uniform liquid to obtain the liposome.

9. Use of the liposome according to any one of claims 5 to 7 in the preparation of an antibacterial product.

10. An antibacterial product, characterized in that: The invention comprises the liposome according to any one of claims 5 to 7.

Images